Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low molecular weight heparin Clear all
Completed Phase 4 Interventional Results available

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

NCT02464969
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Standard of Care
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
0 Days to 17 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

NCT00402467
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, (BAY59-7939), Enoxaparine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 8, 2026, 4:56 PM EDT
Completed No phase listed Observational

Emulation of the RECORD3 Trial Using Healthcare Claims Data

NCT07599384
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
149,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Effects of Exercise in Combination With Epoetin Alfa

NCT00577096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
Drug · Behavioral · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

NCT00952380
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dalteparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
17
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

NCT01094886
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
Interventions
Rivaroxaban
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 8, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

NCT05171075
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Abelacimab, Dalteparin
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Evanston, Illinois • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 8, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional

Heparin Anticoagulation in Septic Shock

NCT03378466
View directory record Official record
Conditions
Septic Shock, Vasodilatory Shock
Interventions
Unfractionated heparin, Venous thromboprophylaxis (VTE)
Drug · Other
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

NCT02072434
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Edoxaban, Warfarin, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
2,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 8, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

NCT00426127
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Docetaxel, Liposomal Doxorubicin, Enoxaparin
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 8, 2026, 4:56 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19

NCT04377997
View directory record Official record
Conditions
Cardiovascular Diseases, COVID-19
Interventions
Enoxaparin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT

NCT04504318
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 8, 2026, 4:56 PM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 8, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

NCT06004674
View directory record Official record
Conditions
Adverse Pregnancy Outcome
Interventions
Lovenox 40mg
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

NCT06118957
View directory record Official record
Conditions
Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 8, 2026, 4:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

NCT01029821
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Low-Molecular-Weight Heparin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

NCT02981472
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
28 Days to 17 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 2Phase 3 Interventional

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

NCT00902928
View directory record Official record
Conditions
Venous Thromboembolism, Arthroplasty, Replacement, Hip
Interventions
YM150, enoxaparin
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 8, 2026, 4:56 PM EDT
Withdrawn Phase 4 Interventional

Timing of VTE Prophylaxis in TBI

NCT03081169
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
Interventions
Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 8, 2026, 4:56 PM EDT
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

NCT00413374
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 8, 2026, 4:56 PM EDT
Terminated Phase 4 Interventional Results available

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389
View directory record Official record
Conditions
COVID-19
Interventions
Enoxaparin sodium, Unfractionated heparin, Fondapariniux, Argatroban
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 8, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 8, 2026, 4:56 PM EDT